![]() ![]() ![]() Novamind will host the LSD Clinical Trial at its Draper, Utah research site, further strengthening its track record of hosting neuropsychiatry and psychedelic clinical trials. The multi-site LSD Clinical Trial plans to enroll 200 participants with dosing expected later this year. The primary objective of the study is to determine the reduction in anxiety symptoms for up to twelve weeks after a single administration of MindMed's proprietary drug candidate, MM-120, a pharmacologically optimized form of LSD being developed for GAD and other brain-based disorders. The LSD Clinical Trial is the most advanced program in MindMed's clinical drug development pipeline and is the first commercial study of LSD in over 40 years. MindMed is a clinical-stage biotech company developing the next generation of psychedelic-inspired medicines and therapies. (NASDAQ:MNMD), (NEO:MMED) ("MindMed") to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder (GAD) in adults ("LSD Clinical Trial"). (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce it has been selected by Mind Medicine, Inc. The decision of the principal regulator under the Legislation is that the Order Sought is granted.TORONTO, ON / ACCESSWIRE / Ma/ Novamind Inc. The principal regulator is satisfied that the order meets the test set out in the Legislation for the principal regulator to make the order. the Filer is not in default of securities legislation in any jurisdiction. the Filer is applying for an order that the Filer has ceased to be a reporting issuer in all of the jurisdictions of Canada in which it is a reporting issuer andĥ. no securities of the Filer, including debt securities, are traded in Canada or another country on a marketplace as defined in National Instrument 21-101 Marketplace Operation or any other facility for bringing together buyers and sellers of securities where trading data is publicly reported Ĥ. the outstanding securities of the Filer, including debt securities, are beneficially owned, directly or indirectly, by fewer than 15 securityholders in each of the jurisdictions of Canada and fewer than 51 securityholders in total worldwide ģ. the Filer is not an OTC reporting issuer under Multilateral Instrument 51-105 Issuers Quoted in the U.S. This order is based on the following facts represented by the Filer:ġ. Terms defined in National Instrument 14-101 Definitions and MI 11-102 have the same meaning if used in this order, unless otherwise defined. Under the Process for Cease to be a Reporting Issuer Applications (for a passport application):Ī) the Ontario Securities Commission is the principal regulator for this application andī) the Filer has provided notice that subsection 4C.5(1) of Multilateral Instrument 11-102 Passport System (" MI11-102") is intended to be relied upon in Alberta, British Columbia and Québec. The principal regulator in the Jurisdiction has received an application from the Filer for an order under the securities legislation of the Jurisdiction of the principal regulator (the "Legislation") that the Filer has ceased to be a reporting issuer in all jurisdictions of Canada in which it is a reporting issuer (the " Order Sought"). ![]() JIN THE MATTER OF THE SECURITIES LEGISLATION OF ONTARIO (the "Jurisdiction") AND IN THE MATTER OF THE PROCESS FOR CEASE TO BE A REPORTING ISSUER APPLICATIONS AND IN THE MATTER OFNOVAMIND INC. National Policy 11-206 Process for Cease to be a Reporting Issuer Applications - issuer deemed to be no longer a reporting issuer under securities legislation. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |